LGND
Ligand Pharmaceuticals Incorporated
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 1992-11-18
$313.52
+6.50 (+2.12%)
last quote
Want the full multi-source brief on LGND?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$313.52
High
$317.76
Low
$309.46
Previous close
$307.02
Fundamentals
Market cap
$6.14B
P/E (TTM)
31.14x
P/S (TTM)
21.14x
P/B
3.66x
Gross margin
95.43%
Operating margin
32.61%
Net margin
67.88%
Rev growth (YoY)
54.89%
EPS growth (YoY)
—
ROE
20.06%
52W high
$326.63
52W low
$175.89
Beta
1.27x
Industry peers
by market cap
Recent SEC filings
CIK 886163filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 1d
Oracle, Nike upgraded: Wall Street's top analyst calls
Oracle, Nike upgraded: Wall Street's top analyst calls
Yahoo · 4d
Ligand Pharmaceuticals Sees Strong Royalty Growth Ahead of Investor Day, Oppenheimer Says
Ligand Pharmaceuticals (LGND) raised its 2026 adjusted EPS guidance but maintained its royalty and t
Yahoo · 4d
Ligand Pharmaceuticals (LGND) Stock Price Ignores Q3 Earnings Losses And Royalty Strength
Ligand Pharmaceuticals just posted Q3 2026 results, and the story the numbers tell is very different from the mood on the screen. The stock is up about 1.2% in Friday trading, a calm reaction for a quarter that paired a reported net loss of US$28.5m with a powerful royalty engine. Royalty revenue reached US$70.3m, and management lifted full year adjusted diluted earnings per share guidance to US$9
Yahoo · 4d
Ligand (LGND) Q3 2026 Earnings Call Transcript
Royalty revenue surged 51% on XOMA acquisition and Filspari momentum.
Yahoo · 4d
Ligand Pharmaceuticals Incorporated Q3 2026 Earnings Call Summary
Moby summary of Ligand Pharmaceuticals Incorporated's Q3 2026 earnings call
Benzinga · 4d
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $357
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $345 to $357.
SeekingAlpha · 5d
Ligand Pharmaceuticals Incorporated 2026 Q3 - Results - Earnings Call Presentation
2026-10-30. The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with their 2026 Q3 earnings call.
SeekingAlpha · 5d
Ligand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDTCompany ParticipantsMelanie Herman - Executive Director of...
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial